Lyme, Mold, and the Diagnostic Blind Spots Slowing Cognitive Recovery
There are few areas in functional medicine that create more confusion than chronic infections and mold.
Not because the tools don’t exist. But because knowing what to test, when to test, and how to interpret it is far from straightforward.
That was the focus of this week’s TruNeura Mastermind, where Dr. Kristine Burke led a deep, practical discussion on one of the most misunderstood areas in cognitive decline care.
The Problem: Too Many Signals, Not Enough Clarity
Most practitioners have encountered this:
A patient with cognitive decline
Multiple possible drivers
Inconsistent or inconclusive testing
And no clear sequencing strategy
You can run Lyme tests.
You can run mold tests.
You can even find positives.
But then comes the harder question:
Does this actually matter for this patient right now?
That’s where many clinicians get stuck.
Dr. Burke’s Framework: Clarity Through Sequencing
What made this session powerful was not just the depth of knowledge. It was the structure.
Dr. Burke walked through a clear, stepwise approach to navigating:
When Lyme testing is meaningful vs misleading
Why antibody results alone are not enough
How to distinguish past exposure from active immune burden
When deeper testing changes clinical decisions
One of the most important distinctions:
Presence does not equal problem.
Many patients show evidence of exposure to infections like Lyme or co-infections. But not all of those infections are actively driving inflammation.
Without that distinction, treatment becomes guesswork.
The Overlooked Link: Why Mold Comes First
A major theme throughout the discussion:
You cannot accurately assess chronic infections without addressing mold.
Why?
Because mold and mycotoxins:
Suppress immune function
Distort test results
Reactivate latent infections
And prevent the body from regaining control
This is where many protocols fail.
Practitioners chase infections… When the immune system was never capable of resolving them in the first place.
Why This Is So Challenging
There is no single test that gives a definitive answer.
Instead, clinicians are navigating:
Imperfect data
Variable immune responses
Financial constraints for patients
And constantly shifting clinical signals
As Dr. Burke emphasized, this is not a checklist.
It’s an evolving clinical strategy.
What Made This Session Different
Beyond the science, what stood out was the level of practical clarity:
How to think through ambiguous results
How to avoid over-testing or over-treating
How to sequence decisions based on physiology, not assumptions
How to balance precision with real-world constraints
This is the kind of insight most practitioners don’t get from courses or conferences.
It comes from working through real cases, in real time, with experienced clinicians.
Why This Matters for Your Practice
Many cognitive decline cases plateau not because clinicians lack knowledge…
But because key drivers like mold and chronic infections are:
Misinterpreted
Poorly sequenced
Or missed entirely
Getting this right can change the entire trajectory of care.
What This Looks Like in Practice
During the session, a clinician dropped this in the chat:
“Thank you… for being here and sharing your clinical expertise.”
It’s a small comment, but it captures something bigger.
These aren’t theoretical conversations. They’re real-time clarity on the cases that usually stall progress.
Thank you! It is so hard to help people understand the dangers of mold. Here in the humid South, we in Mississippi lead the nation in mortality from dementia. We need more physicians using Functional Medicine and TruNeura.